Should Anal Pap Smears Be a Standard of Care in HIV Management?

Size: px
Start display at page:

Download "Should Anal Pap Smears Be a Standard of Care in HIV Management?"

Transcription

1 Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine

2 Short Answer: NO

3 But HPV types are oncogenic and linked to cervical cancer (especially 16 &18, but also 31, 33, 35, 39, 45, 51, 52, 58). Same strains infect anal mucosa. Anal cancer is increased in MSM So, anal screening may be a cost effective, life-saving procedure just as it is for women with cervical HPV.

4 HPV and Anogenital Warts Perianal warts HPV 6 and 11 responsible for >90% of anogenital warts 1 Peak prevalence 2 Women years of age (6.2/1,000 person years) Men years of age (5.0/1,000 person years) Clinically apparent in ~1% of sexually active US adult population 3 1. Jansen KU, Shaw AR. Annu Rev Med. 2004;55: Insinga RP, Dasbach EF, Myers ER. Clin Infect Dis. 2003;36: Koutsky L. Am J Med. 1997;102:3 8.

5 CERVICAL CANCER/ANAL CANCER BOTH RELATED TO HPV BOTH PRECEDED BY INTRAEPITHELIAL LESIONS BOTH ARISE IN THE TRANSFORMATION ZONE - JUNCTURE BETWEEN COLUMNAR EPITHELIUM RECTUM AND THE SQUAMOUS EPITHELIUM OF ANUS

6 CERVICAL CANCER/ANAL CANCER INCIDENCE OF CERVICAL CANCER PRE PAP SMEAR SCREENING CASES /100,000 INDIVIDUALS

7 CERVICAL CANCER/ANAL CANCER INCIDENCE OF CERVICAL CANCER PRE PAP SMEAR SCREENING CASES /100,000 INDIVIDUALS INCIDENCE OF CERVIVAL CANCER POST- PAP SMEAR SCREENING 8-10 CASES/100,000 INDIVIDUALS

8 CERVICAL CANCER/ANAL CANCER INCIDENCE OF CERVICAL CANCER PRE PAP SMEAR SCREENING CASES /100,000 INDIVIDUALS INCIDENCE OF CERVIVAL CANCER POST- PAP SMEAR SCREENING 8-10 CASES/100,000 INDIVIDUALS BEFORE HIV EPIDEMIC, INCIDENCE OF ANAL CANCER 37 CASES/100,000 AMONG MEN WHO HAVE SEX WITH MEN(MSM) INCIDENCE OF ANAL CANCER IS EVEN HIGHER AMONG HIV-POSITIVE MEN AND WOMEN (J Natl Cancer Inst 2000; 92: )

9 CERVICAL CANCER/ANAL CANCER RELATIVE RISK OF INVASIVE ANAL CA WAS 37 IN HIV POSITIVE MEN AND 6.8 IN HIV POSITIVE WOMEN COMPARED TO THE GENERAL POPULATION (US AIDS CANCER REGISTRY MATCH STUDY)

10 CERVICAL CANCER/ANAL CANCER RELATIVE RISK OF INVASIVE ANAL CA WAS 37 IN HIV POSITIVE MEN AND 6.8 IN HIV POSITIVE WOMEN COMPARED TO THE GENERAL POPULATION (US AIDS CANCER REGISTRY MATCH STUDY). IN SAN FRANCISCO, CALIFORNIA, THE INCIDENCE OF ANAL CA AMONG ALL WHITE AND HISPANIC MEN AGED Y/O RANGED FROM 3 CASES/100,OOO INDIVIDUALS IN TO >14 CASES/100,000 INDIVIDUALS IN CASES OF ANAL CA IN MEN AND 27 IN WOMEN IN ALL AGE GROUPS WAS REPORTED IN , FOR SAN FRANCISCO COUNTY.

11 HUMAN PAPPILOMAVIRUS(HPV) ONE OF THE MOST COMMON SEXUALLY TRANSMITTED AGENT HIGHLY PREVALENT IN HIV-INFECTED PATIENTS MULTIPLE HPV TYPES COINFECTION FOUND IN CYTOLOGY

12 HUMAN PAPPILOMAVIRUS(HPV) LIKE CERVICAL HPV INFECTION, CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CEVICAL CA, ANAL HPV INFECTION IS AN IMPORTANT RISK FACTOR FOR ANAL INTRAEPETHELIAL NEOPLASIA (AIN) AND ANAL CANCER.

13 HUMAN PAPPILOMAVIRUS(HPV) LIKE CERVICAL HPV INFECTION, CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CA, ANAL HPV INFECTION IS AN IMPORTANT RISK FACTOR FOR ANAL INTRAEPETHELIAL NEOPLASIA (AIN) AND ANAL CANCER. MEN- PREVALENCE OF HPV 60% HIV NEG. MSM AND 93% IN HIV + MSM. (JID 1998; 177:361-7)

14 HUMAN PAPPILOMAVIRUS(HPV) LIKE CERVICAL HPV INFECTION, CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CA, ANAL HPV INFECTION IS AN IMPORTANT RISK FACTOR FOR ANAL INTRAEPETHELIAL NEOPLASIA (AIN) AND ANAL CANCER. MEN- PREVALENCE OF HPV 60% HIV NEG. MSM AND 93% IN HIV + MSM. (JID 1998; 177:361-7) WOMEN- 76% OF 223 HIV + WOMEN HAD ANAL HPV AS DID 42% OF HIGH RISK HIV NEG. WOMEN ( IVD, SEX WORKERS) (WOMEN S INTERAGENCY HIV STUDY) ANAL HPV INFECTION IS MORE COMMON THAN CERVICAL HPV INFECTION AMONG BOTH HIV + AND HIGH RISK HIV NEG WOMEN. (WOMEN S INTERAGENCY HIV STUDY)

15 Classification Terminology for Cervical Cytology: The 2001 Bethesda System Normal 1 ASCUS 2 LSIL 3 HSIL 3 Two types of atypical squamous cells (ASC) 4 Atypical squamous cells of undetermined significance (ASCUS) Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions (ASC-H) Squamous intraepithelial lesions (SIL) 4 Low-grade SIL (LSIL): Mild dysplasia, cervical intraepithelial neoplasia 1 (CIN 1) High-grade SIL (HSIL): Moderate and severe dysplasia, CIN 2/3, carcinoma in situ (CIS)

16 ANAL INTRAEPITHELIAL NEOPLASIA (AIN) AS IN THE CERVIX, ANUS DISPLAYS CHANGES RANGING FROM AIN I TO III. ANAL CYTOLOGY ASCUS- ATYPICAL SQUAMOUS CELLS OF UNKOWN SIGNIFICANCE; NON SPECIFIC IN CYTOLOGY BUT OFTEN ASSOCIATED W/ AIN ON HIGH RESOLUTION ANOSCOPY (HRA) AIN I - NOT THOUGHT TO PROGRESS DIRECTLY TO ANAL CA (LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION/LSIL) AIN II AND AIN III - LIKELY TRUE PRECURSORS TO ANAL CA (HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION/HSIL)

17 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) IN A STUDY FROM SAN FRANCISCO (J AIDS HUM RETROV 1998;17:314-9) 2 YEAR F/U ANAL CYTOLOGY

18 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) IN A STUDY FROM SAN FRANCISCO (J AIDS HUM RETROV 1998;17:314-9) 2 YEAR F/U ANAL CYTOLOGY NO ANAL DX BASELINE 32% HIV POSITIVE PROGRESSED AIN I 9% HIV NEG. PROGRESSED TO AIN I

19 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) IN A STUDY FROM SAN FRANCISCO (J AIDS HUM RETROV 1998;17:314-9) 2 YEAR F/U ANAL CYTOLOGY NO ANAL DX BASELINE 32% HIV POSITIVE PROGRESSED AIN I 9% HIV NEG. PROGRESSED TO AIN I AIN I BASELINE 30% OF PATIENTS HAD F/U NORMAL CYTOLOGY, ALL HIV NEG. > 50% HIV + MEN DEVELOPED AIN II OR III

20 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) IN A STUDY FROM SAN FRANCISCO (J AIDS HUM RETROV 1998;17:314-9) 2 YEAR F/U ANAL CYTOLOGY NO ANAL DX BASELINE 32% HIV POSITIVE PROGRESSED AIN I 9% HIV NEG. PROGRESSED TO AIN I AIN I BASELINE 30% OF PATIENTS HAD F/U NORMAL CYTOLOGY, ALL HIV NEG. > 50% HIV + MEN DEVELOPED AIN II OR III IN A STUDY FROM SEATTLE ( AIDS 1995; 9: ) MSM W/ NO ANAL DX AT BASELINE 15% HIV POSITIVE DEVELOPED AIN II OR III/21 MONTHS VS 8 % HIV NEG.

21 SAN FRANCISCO FOUR YEAR INCIDENCE OF AIN II AND III IN HIV POSITIVE MSM AND HIV NEG. MSM(CID 2002; 35: )

22 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) HIV POSITIVE WITH OR WITHOUT HISTORY OF ANAL INTERCOURSE 50 HIV+ (36 MEN, 14 WOMEN) ANAL HPV DNA WAS DETECTED AS FREQUENTLY IN PATIENTS REPORTING NO ANAL INTERCOURSE AS IN MSM (EUR J DERMAT 2003, 13:367-71)

23 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) HIV POSITIVE WITH OR WITHOUT HISTORY OF ANAL INTERCOURSE 50 HIV+ (36 MEN, 14 WOMEN) ANAL HPV DNA WAS DETECTED AS FREQUENTLY IN PATIENTS REPORTING NO ANAL INTERCOURSE AS IN MSM (EUR J DERMAT 2003, 13:367-71) 36 MEN HIV POSITIVE, NO H/O RECEPTIVE ANAL INTERCOURSE PREVALENCE HPV 33% AND AIN 23% (JID 2004, 190;: )

24 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) HIV POSITIVE WITH OR WITHOUT HISTORY OF ANAL INTERCOURSE 50 HIV+ (36 MEN, 14 WOMEN) ANAL HPV DNA WAS DETECTED AS FREQUENTLY IN PATIENTS REPORTING NO ANAL INTERCOURSE AS IN MSM (EUR J DERMAT 2003, 13:367-71) 36 MEN HIV POSITIVE, NO H/O RECEPTIVE ANAL INTERCOURSE PREVALENCE HPV 33% AND AIN 23% (JID 2004, 190;: ) 50 HIV-INFECTED PATIENTS, IVDU, DENIED ANAL INTERCOURSE 67 HIV POSITIVE MSM HIV+/ IVDU PREVALENCE ANAL HPV 46%; AIN 36% PREVALENCE OF AIN II OR III DID NOT DIFER AMONG THE 2 GROUPS (ANN INTERN MED 2003, 183:453-59)

25 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) ONCE AIN II OR III IS FOUND IN THE ANAL EPITHELIUM IT RARELY REGRESSES EVEN IN HIV NEG. INDIVIDUALS.

26 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) ONCE AIN II OR III IS FOUND IN THE ANAL EPITHELIUM IT RARELY REGRESSES EVEN IN HIV NEG. INDIVIDUALS. THERE HAS BEEN NO STUDY THAT HAS ESTABLISHED THE RATE OF PROGRESSION FROM AIN II OR III TO ANAL CA; IT LIKELY REQUIRES DECADES. THERE HAS BEEN EXTENSIVE EXPIRIENCE WITH BOWEN DX (PERIANAL AIN II OR III) OF WHICH 5% OF LESIONS UNDERGO MALIGNANT CHANGES.

27 ANAL INTRAEPITHELIAL NEOPLASIA(AIN) ONCE AIN II OR III IS FOUND IN THE ANAL EPITHELIUM IT RARELY REGRESSES EVEN IN HIV NEG. INDIVIDUALS. THERE HAS BEEN NO STUDY THAT HAS STABLISHED THE RATE OF PROGRESSION FROM AIN II OR III TO ANAL CA; IT LIKELY REQUIRES DECADES.

28 CURRENT DATA THE INCIDENCE OF ANAL CANCER CONTINUES TO INCREASE DESPITE HAART. (AIDS 2005; 19: )

29

30

31 HSIL LSIL ASCUS Normal Unsatisfactory Declined 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0%

32 100% 80% 60% 40% 20% Ca in situ AIN II/III AIN I Normal 0% ASCUS LSIL HSIL

33 MIAMI VA MEDICAL CENTER EXPERIENCE Screening was accepted by patients. High rate of unsatisfactory specimens as providers became proficient. A successful screening program requires collaborative efforts of pathologists and proctologists.

34 Conclusion Persons with HIV disease as a group are at increased risk for both anal HPV infection and anal cancer. Based upon current knowledge of HPV and anal cancer in this population, Screening is indicated. The answer to the question should anal pap smears become a standard of care? Should change to YES.

35

36

HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco

HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco Anal cytology and anal cancer in HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco April 10, 2010 Disclosures Merck and Co: Research grant support, advisory boards

More information

Understanding Your Pap Test Results

Understanding Your Pap Test Results Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities

More information

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates

More information

HPV-related papillomatous-condylomatous lesions in female anogenital area

HPV-related papillomatous-condylomatous lesions in female anogenital area HPV-related papillomatous-condylomatous lesions in female anogenital area Theo Panoskaltsis MD, FRCOG, CCST (UK) Epidemiology Anal cancer is increasing in both men and women Groups at risk: - HIV (+)

More information

Disclosures Teresa M Darragh, MD

Disclosures Teresa M Darragh, MD Below the Belt: Screening for HPV-associated Cancers Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Disclosures Teresa M Darragh, MD Hologic: Research

More information

Colposcopy. Attila L Major, MD, PhD

Colposcopy. Attila L Major, MD, PhD Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000

More information

Bottoms UP HIV and Anal Cancer from Screening to Prevention

Bottoms UP HIV and Anal Cancer from Screening to Prevention Bottoms UP HIV and Anal Cancer from Screening to Prevention Paul MacPherson PhD, MD, FRCPC Associate Professor Division of Infectious Diseases University of Ottawa The New Reality Normal or near-normal

More information

Making Sense of Cervical Cancer Screening

Making Sense of Cervical Cancer Screening Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because

More information

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa

More information

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN. CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee

More information

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives

More information

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer

More information

Anal Dysplasia Screening

Anal Dysplasia Screening Ontario Health Technology Assessment Series 2007; Vol. 7, No. 4 Anal Dysplasia Screening An Evidence-Based Analysis June 2007 Medical Advisory Secretariat Ministry of Health and Long-Term Care Suggested

More information

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Cervical Screening for Dysplasia and Cancer in Patients with HIV Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase

More information

Update on Anal HPV. Medical Management of AIDS. December 9, Joel Palefsky Department of Medicine University of California, San Francisco

Update on Anal HPV. Medical Management of AIDS. December 9, Joel Palefsky Department of Medicine University of California, San Francisco Update on Anal HPV Medical Management of AIDS December 9, 2017 Joel Palefsky Department of Medicine University of California, San Francisco Disclosures Merck and Co- research and travel support Antiva

More information

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is

More information

BC Cancer Cervix Screening 2015 Program Results. February 2018

BC Cancer Cervix Screening 2015 Program Results. February 2018 BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...

More information

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This

More information

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health

More information

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals Historical Named after George Papanicolaou, a Greek American Studied cervical epithelium in menstrual cycle of guinea

More information

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%

More information

How might we implement screening for anal cancer in HIV-positive patients?

How might we implement screening for anal cancer in HIV-positive patients? Objective How might we implement screening for anal cancer in HIV-positive patients? Identify the elements required to set up an anal cancer screening and prevention program J. Michael Berry, MD Associate

More information

Pathology of the Cervix

Pathology of the Cervix Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading

More information

Cancer in the LGBTQ Community. Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine

Cancer in the LGBTQ Community. Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine + Cancer in the LGBTQ Community Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine + Objectives Discuss the possible reasons that LGBTQ people have a disproportionate

More information

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse

More information

MEDICAL POLICY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14 SUBJECT: HIGH RESOLUTION ANOSCOPY

MEDICAL POLICY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14 SUBJECT: HIGH RESOLUTION ANOSCOPY MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

Cytyc Corporation - Case Presentation Archive - June 2003

Cytyc Corporation - Case Presentation Archive - June 2003 ThinPrep General Cytology History: Asymptomatic 35 Year Old Male Specimen type: Anal Cytology - This specimen was collected using a Dacron swab under proctoscopic visualization. This case was provided

More information

Jean Anderson, MD Catherine Sewell, MD, MPH

Jean Anderson, MD Catherine Sewell, MD, MPH Jean Anderson, MD Catherine Sewell, MD, MPH To review diagnosis and management of HPV disease in the setting of HIV infection and address controversies HIV-infected women have: higher prevalence and incidence

More information

Cervical Cancer Screening Guidelines Update

Cervical Cancer Screening Guidelines Update Frontier AIDS Education and Training Center Cervical Cancer Screening Guidelines Update Hillary Liss, MD Harborview Medical Center, Madison and Adult Medicine Clinics Frontier AETC, Medical Program Director

More information

Clinical Practice Guidelines June 2013

Clinical Practice Guidelines June 2013 Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early

More information

What is a Pap smear?

What is a Pap smear? Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years

More information

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

SESSION J4. What's Next? Managing Abnormal PAPs in 2014 37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines

More information

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013 Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely

More information

MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY

MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including

More information

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care

More information

I have no financial interests to disclose.

I have no financial interests to disclose. Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Chapter 10: Pap Test Results

Chapter 10: Pap Test Results Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics

More information

Human Papillomavirus

Human Papillomavirus Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and

More information

Done by khozama jehad. Neoplasia of the cervix

Done by khozama jehad. Neoplasia of the cervix Done by khozama jehad Neoplasia of the cervix An overview of cervical neoplasia very import. Most tumors of the cervix are of epithelial origin and are caused by oncogenic strains of human papillomavirus

More information

The Anal Canal and Perianus: HPV-Related Disease

The Anal Canal and Perianus: HPV-Related Disease CHAPTER 17 TERESA M. DARRAGH J. MICHAEL BERRY NAOMI JAY JOEL M. PALEFSKY The Anal Canal and Perianus: HPV-Related Disease 17.1 EPIDEMIOLOGY OF ANAL HPV INFECTION, ANAL INTRAEPITHELIAL NEOPLASIA, AND ANAL

More information

Cervical Dysplasia and HPV

Cervical Dysplasia and HPV Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk

More information

CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.

CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb. CERVIX MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb. CERVIX Most cervical lesions are: Most are Cervicitis. cancers ( common in women worldwide). CERVICITIS Extremely

More information

Cervical Precancer: Evaluation and Management

Cervical Precancer: Evaluation and Management TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of

More information

MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14, 09/17/15, 9/15/16 ARCHIVED DATE: 09/21/17

MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14, 09/17/15, 9/15/16 ARCHIVED DATE: 09/21/17 MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

HCT Medical Policy. High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014.

HCT Medical Policy. High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014. HCT Medical Policy High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014 Medical Policies are developed by HealthyCT to assist in administering plan

More information

X-Treme Primary Care: HPV and STIs. Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers

X-Treme Primary Care: HPV and STIs. Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers X-Treme Primary Care: HPV and STIs Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers Learning Objectives Review recommendations for HPV related cancer screening in

More information

Focus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010

Focus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010 HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,

More information

HPV Epidemiology and Natural History

HPV Epidemiology and Natural History HPV Epidemiology and Natural History Rachel Winer, PhD, MPH Associate Professor Department of Epidemiology University of Washington School of Public Health rlw@uw.edu Human Papillomavirus (HPV) DNA virus

More information

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

chapter 4. The effect of oncogenic HPV on transformation zone epithelium chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence

More information

I have no financial interests in any product I will discuss today.

I have no financial interests in any product I will discuss today. Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,

More information

HPV Testing & Cervical Cancer Screening:

HPV Testing & Cervical Cancer Screening: HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success

More information

The society for lower genital tract disorders since 1964.

The society for lower genital tract disorders since 1964. The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

Estimated New Cancers Cases 2003

Estimated New Cancers Cases 2003 Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz Estimated New Cancers Cases 2003 Images removed due to copyright reasons.

More information

The Korean Journal of Cytopathology 13(1): 14-20, 2002

The Korean Journal of Cytopathology 13(1): 14-20, 2002 13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous

More information

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted? CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses

More information

Eradicating Mortality from Cervical Cancer

Eradicating Mortality from Cervical Cancer Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus

More information

Although rare, a significant increase in incidence

Although rare, a significant increase in incidence Original Research Concurrent Anal Human Papillomavirus and Abnormal Anal Cytology in Women With Known Cervical Dysplasia Jacqueline Lammé, MD, Tina Pattaratornkosohn, MD, Joselyn Mercado-Abadie, MD, Addie

More information

Who Should Have a Pap Test and How Frequently? 1

Who Should Have a Pap Test and How Frequently? 1 Chapter 3: Screening On completion of this section, the learner will be able to: 1. Describe who should have a Pap test and how frequently. 2. Identify who should be excluded from Pap tests and who should

More information

GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED

GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version

More information

Promoting Cervical Screening Information for Health Professionals. Cervical Cancer

Promoting Cervical Screening Information for Health Professionals. Cervical Cancer Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360

More information

Editorial Process: Submission:10/31/2017 Acceptance:09/09/2018

Editorial Process: Submission:10/31/2017 Acceptance:09/09/2018 RESEARCH ARTICLE Editorial Process: Submission:10/31/2017 Acceptance:09/09/2018 Evaluation of Anal Cytology in Women with History of Abnormal Pap Smear, Cervical Intraepithelial Neoplasia, Cervical Cancer

More information

PAP smear. (Papanicolaou Test)

PAP smear. (Papanicolaou Test) PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European

More information

7. HUMAN PAPILLOMAVIRUS INFECTION AND DISEASE IN THE HIV+ INDIVIDUAL

7. HUMAN PAPILLOMAVIRUS INFECTION AND DISEASE IN THE HIV+ INDIVIDUAL 7. HUMAN PAPILLOMAVIRUS INFECTION AND DISEASE IN THE HIV+ INDIVIDUAL JENNIFER E. CAMERON *, MICHAEL E. HAGENSEE * Tulane Health Sciences Center,Tulane Medical School, New Orleans, LA Department of Medicine,

More information

Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC

Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC Taking Laboratory Coding for a Spin Corrie Alvarez, CPC, CPMA, CPC-I, CEDC Agenda Overview of Laboratory Discuss Common Laboratory Terms Coding Guidelines Review Drug Testing, Anatomical Pathology Discuss

More information

PREVENTION OF CERVICAL CANCER

PREVENTION OF CERVICAL CANCER PREVENTION OF CERVICAL CANCER Author: Dr R. Fuentes MBchb, Havana Spec. OB,GY-Havana- 2011 CONTENT TABLE Abbreviations 2 Introduction 4 The natural history of Cervical cancer 4 Risk Factors 4 Incidence

More information

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

!#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ !"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology

More information

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16 WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 05/01/95 ANY MISSING OR INCOMPLETE TEST RESULTS

More information

Cervical Cancer Screening. David Quinlan December 2013

Cervical Cancer Screening. David Quinlan December 2013 Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for

More information

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures

More information

HPV Infection in Fe-male Patients: Methods of Detection. Topics. West Coast Pathology Laboratories WEST COAST PATHOLOGY LABORATORIES

HPV Infection in Fe-male Patients: Methods of Detection. Topics. West Coast Pathology Laboratories WEST COAST PATHOLOGY LABORATORIES WEST COAST PATHOLOGY LABORATORIES HPV Infection in Fe-male Patients: Methods of Detection John Compagno, MD, Medical Director Topics Pap cytology still an excellent test made better Value of HPV Genotyping

More information

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases

More information

Il percorso sulla diagnosi del carcinoma anale. Cristina Mussini

Il percorso sulla diagnosi del carcinoma anale. Cristina Mussini Il percorso sulla diagsi del carcima anale Cristina Mussini Standardized Incidence Ratio (SIR) of AIDS-defining cancers in 99.309 pts with HIV/AIDS from French registry-linkage study in different cart

More information

The Korean Journal of Cytopathology 15 (1) : 17-27, 2004

The Korean Journal of Cytopathology 15 (1) : 17-27, 2004 5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV

More information

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).

More information

Cervical Cancer Screening

Cervical Cancer Screening Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)

More information

Cervical Cancer Screening

Cervical Cancer Screening Cervical Cancer Screening MEGAN CHENEY, MD MPH MEDICAL DIRECTOR, THE WOMEN S CENTER ASSISTANT DIRECTOR, BGSMC OBGYN RESIDENCY PROGRAM SECTION CHIEF, THE WOMEN S HEALTH INSTITUTE Objectives Understand proper

More information

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Management Algorithms for Abnormal Cervical Cytology and Colposcopy Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent

More information

Cervical Cancer 4/27/2016

Cervical Cancer 4/27/2016 Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about

More information

HPV infection and intraepithelial lesions from the anal region: how to diagnose?

HPV infection and intraepithelial lesions from the anal region: how to diagnose? HPV infection and intraepithelial lesions from the anal region: how to diagnose? Review Article ABSTRACT In the last years, the prevalence of HPV infection in the anal region has increased, especially

More information

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology United States and Canadian Academy of Pathology 102 nd Annual Meeting Baltimore, Maryland Christina S. Kong, M.D.

More information

HPV-Associated Disease and Prevention

HPV-Associated Disease and Prevention HPV-Associated Disease and Prevention Odessa Regional Medical Center May 28, 2015 Erich M. Sturgis, MD, MPH Professor Department of Head & Neck Surgery Department of Epidemiology Christopher & Susan Damico

More information

January 15, 2009 (202) PROPOSALS TO IMPROVE CYTOLOGY PROFICIENCY TESTING REQUIRED BY THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988

January 15, 2009 (202) PROPOSALS TO IMPROVE CYTOLOGY PROFICIENCY TESTING REQUIRED BY THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988 DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs CMS FACT SHEET FOR IMMEDIATE RELEASE Contact:

More information

HPV AND CERVICAL CANCER

HPV AND CERVICAL CANCER HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND

More information

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.

More information

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006 anitoba Cervical Cancer Screening Program Operations & Statistical Report 2005 and 2006 1 MCCSP 2005-2006 Report ANITOBA CERVICAL CANCER SCREENING PROGRAM 2005 and 2006 Operations & Statistical Report

More information

Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia

Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 1 Number 2 Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia I Mansoor Citation I Mansoor. Profile Of Cervical Smears

More information

Your Colposcopy Visit

Your Colposcopy Visit Introduction Welcome to the colposcopy clinic. This booklet tells you about. The colposcopy examination.. Tests that are done in the colposcopy clinic.. What these tests look for Take a few minutes to

More information

Histopathology: Cervical HPV and neoplasia

Histopathology: Cervical HPV and neoplasia Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about

More information

The Role of Epidemiologic Studies in Establishing HPV as a Cause of Cancer. April 2, 2008 Margaret M. Madeleine, PhD. Outline

The Role of Epidemiologic Studies in Establishing HPV as a Cause of Cancer. April 2, 2008 Margaret M. Madeleine, PhD. Outline The Role of Epidemiologic Studies in Establishing HPV as a Cause of Cancer April 2, 2008 Margaret M. Madeleine, PhD Outline HPV in Cervical Cancer Basics: Incidence, screening, and the virus Causal criteria

More information

Genital Human Papillomavirus (HPV) Infections

Genital Human Papillomavirus (HPV) Infections Genital Human Papillomavirus (HPV) Infections January 2008 Etiology... 1 Epidemiology... 1 Prevention... 2 Diagnosis... 3 Management... 6 Treatment... 7 Consideration for Other STIs... 9 Reporting and

More information

CERVICAL CANCER FACTSHEET. What is cervical cancer?

CERVICAL CANCER FACTSHEET. What is cervical cancer? CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up

More information

Recommandations SSGO dépistage cancer du col utérin. Pr Patrick Petignat University Hospitals of Geneva

Recommandations SSGO dépistage cancer du col utérin. Pr Patrick Petignat University Hospitals of Geneva Recommandations SSGO dépistage cancer du col utérin Pr Patrick Petignat University Hospitals of Geneva GRSSGO 2018 Pap test for cervical cancer screening: A success story Introduce essentially by gynecologists

More information

Chapter 2: Disease Burden and Cervical Screening in Ontario

Chapter 2: Disease Burden and Cervical Screening in Ontario Chapter 2: Disease Burden and Cervical Screening in Ontario Learning Objectives On completion of this section, the learner will be able to: 1. Understand human papillomavirus, disease burden, cervical

More information

Management of Abnormal Cervical Cytology and Histology

Management of Abnormal Cervical Cytology and Histology Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline

More information

Cytology Report Format

Cytology Report Format Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College

More information

Alexandra Lydia Hernandez. A dissertation submitted in partial satisfaction of the. requirements for the degree of. Doctor of Philosophy.

Alexandra Lydia Hernandez. A dissertation submitted in partial satisfaction of the. requirements for the degree of. Doctor of Philosophy. Human papillomavirus infection in HIV-seropositive men who have sex with men in both the United States and India: Prevalence, incidence, and risk factors for infection by Alexandra Lydia Hernandez A dissertation

More information

TISSUE TUMOR MARKER EXPRESSION IN

TISSUE TUMOR MARKER EXPRESSION IN TISSUE TUMOR MARKER EXPRESSION IN NORMAL CERVICAL TISSUE AND IN CERVICAL INTRAEPITHELIAL NEOPLASIA, FOR WOMEN WHO ARE AT HIGH RISK OF HPV (HUMAN PAPILLOMA VIRUS INFECTION). Raghad Samir MD PhD Verksamhet

More information

No Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016

No Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016 Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI Medical College of Wisconsin May 6,

More information